Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 7/20 | 0.76 |
| ▸ | AR | P10275 | 7/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.76 |
| ▸ | LMNA | P02545 | 6/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692133 | 1.00 | PGR (0.76) | PGRARNR3C1CYP3A4LMNA | |
| SCHEMBL11511139 | 0.94 | PGR (0.78) | PGRARNR3C1CYP3A4LMNA | |
| Megestrol Acetate SCHEMBL8817569 | 0.87 | AR (1.00) | PGRARNR3C1CYP3A4LMNA | |
| Megestrol Acetate SCHEMBL745 | 0.87 | AR (1.00) | PGRARNR3C1CYP3A4LMNA | |
| Megestrol Acetate SCHEMBL14071675 | 0.87 | AR (1.00) | PGRARNR3C1CYP3A4LMNA | |
| Megestrol Acetate SCHEMBL13941350 | 0.87 | AR (1.00) | PGRARNR3C1CYP3A4LMNA | |
| Megestrol Acetate SCHEMBL13660184 | 0.87 | AR (1.00) | PGRARNR3C1CYP3A4LMNA | |
| Megestrol Acetate SCHEMBL190902 | 0.87 | AR (1.00) | PGRARNR3C1CYP3A4LMNA | |
| Megestrol Acetate SCHEMBL21281326 | 0.87 | AR (1.00) | PGRARNR3C1CYP3A4LMNA | |
| Megestrol Acetate SCHEMBL12998544 | 0.87 | AR (1.00) | PGRARNR3C1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | ENDORECHERCHE, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1321146-A2 | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use | Endorecherche Inc. (CA) | 2003-06-25 | — | — | EP | disclosed |
| US-6541463-B1 | 17-spirolactone derivatives of steroids | ENDORECHERCHE, INC. (CA) | 2003-04-01 | — | — | US | disclosed |
| EP-1094798-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | Endorecherche Inc. (CA) | 2001-05-02 | — | — | EP | disclosed |
| WO-1999046279-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | ENDORECHERCHE, INC. (CA) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | HSD17B11, HSD17B3, HSD17B1 | PGR 521/4885AR 278/4885NR3C1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.